Claudia Zylberberg

Claudia Zylberberg is a prominent figure in the cell and gene therapy industry with over 15 years of experience.1 She is the Co-Founder and Board Chair at Kosten Digital, a company focused on providing digital solutions for AI and machine learning to enable efficient global reach of healthcare solutions.23

Professional Experience

Zylberberg has held several key positions throughout her career:

• Kosten Digital: Co-Founder and Board Chair13
• Akron Bio: Founder, Board Member, and former CEO (2006-2021)1
• Arscience Biotherapeutics: Board Chair1
• Liberty Science Center: Member of the Board of Trustees (since May 2018)1

Entrepreneurial Ventures

Claudia Zylberberg has demonstrated a keen eye for identifying gaps in the healthcare industry and creating companies to address them. She founded:

1. Akron Bio: An innovative company developing, manufacturing, and marketing ancillary materials for cell and gene therapies.1
2. Arscience Bio: Focused on adjuvants and opportunities for biologics to augment and combine with other entities to synergize therapeutics.2
3. Kosten Digital: Providing digital solutions for AI and ML to enable efficient global reach of healthcare solutions.2

Industry Contributions

Zylberberg has been actively involved in various industry organizations:

• Participated in the US Pharmacopoeia, Standards Coordinating Body, ASGCT, ISCT, and ARM.2
• Contributed to book chapters, articles, white papers, and working groups.2
• Nominated as a potential President for the International Society for Cell & Gene Therapy (ICST).2

Vision and Goals

Claudia Zylberberg is dedicated to advancing the field of cell and gene therapy. Her current focus includes:

• Exploring IL2 and IL15 proteins as adjuvants for cell therapies.2
• Investigating digitalization opportunities in patient acquisition and affordability models.2
• Striving to make novel therapies safe, affordable, and accessible to patients.2

Claudia Zylberberg's LinkedIn username is claudia-zylberberg-32a56a5.1